Bisphosphonate-associated osteonecrosis of the jaw: A six-year history of a case

New Zealand Dental Journal

Volumn 107, Issue 3, 2011, Pages 97-100

  Hewson, I D ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN KAPPA CHAIN; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; DEBRIDEMENT; DISEASE COURSE; FOLLOW UP; HUMAN; JAW DISEASE; MALE; MANDIBLE TUMOR; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; RECURRENT DISEASE;

BONE DENSITY CONSERVATION AGENTS; DEBRIDEMENT; DIPHOSPHONATES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN KAPPA-CHAINS; MALE; MANDIBULAR DISEASES; MANDIBULAR NEOPLASMS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; RECURRENCE;

EID: 80155122738     PISSN: 00288047     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C,Terpos E, Dimopoulos MA (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587. (Pubitemid 46211499)
2. Lee MV, Fong EM, Singer FR, Guenette RS (2001) . Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2260.
3. Marx RE (2003). Pamidronate and Zoledronate induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofacial Surg 61: 1115.
4. Migliorati CA (2003). Bisphosphonates and the oral cavity avascular bone necrosis. J Clin Oncol 21: 4253.
5. Migliorati CA, Casiglia J, Epstine J, Jacobsen PL, Siegel MA, Woo SB (2005). Managing the care of patients with bisphosphonate associated osteonecrosis. American Academy of Oral Medicine position paper: J Am Dent Assoc 136: 1658-1668. (Pubitemid 41810027)
6. Migliorati CA, Siegel MA, Elting LS (2006) Bisphosphonate associated osteonecrosis: a long term complication of bisphosphonate treatment. Lancet Oncology 7; 508-514. (Pubitemid 43779167)
7. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervert FKL, Brennan MT (2010) .A systematic review of bisphosphonate osteonecrosis in cancer. Support Care in Cancer 18: 1089-1098.
8. Smith A, WisloffF, Samson D (2006). Guidelines for the diagnosis and management of multiple myeloma. Brit J Haematol 132: 410-541.
9. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukelm FW, Nkenke E (2010). Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18: 449-460.
10. Wang J, Goodger NM, Pogrel MA (2003). Osteonecrosis of the jaws associated with cancer therapy. J Oral Maxillofacial Surg 61 : 1104-1107. (Pubitemid 37064708)
11. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007). Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America: New England J Med 357: 2133-2142 (Pubitemid 350146108)